Bisgaier Charles PhD 4
4 · Gemphire Therapeutics Inc. · Filed Jan 30, 2018
Insider Transaction Report
Form 4
Bisgaier Charles PhD
DirectorChair & Chief Scientific Off.10% Owner
Transactions
- Award
Stock Option (right to buy)
2018-01-28+48,000→ 48,000 totalExercise: $10.10Exp: 2028-01-27→ Common Stock (48,000 underlying)
Footnotes (1)
- [F1]The option vests in a series of 48 successive equal monthly installments on the last day of each month, commencing on the grant date.